drugset / Trial / NCT01028963

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

NCT01028963

Phase 2 Completed 159 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.

Timeline

Start
2010-01
Primary completion
2010-10
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CCX140-B Small molecule
Comparator Pioglitazone Small molecule 30 mg